Molecularly targeted therapies for glioma

Ryuya Yamanaka, Hideyuki Saya

研究成果: Review article査読

22 被引用数 (Scopus)

抄録

Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.

本文言語English
ページ(範囲)717-729
ページ数13
ジャーナルAnnals of Neurology
66
6
DOI
出版ステータスPublished - 12-2009
外部発表はい

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

フィンガープリント 「Molecularly targeted therapies for glioma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル